MCID: PTT006
MIFTS: 56

Pituitary Adenoma malady

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pituitary Adenoma

Aliases & Descriptions for Pituitary Adenoma:

Name: Pituitary Adenoma 12 29 52 14 69
Pituitary Neoplasms 42 69
Adenoma of the Pituitary Gland 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3829
MeSH 42 D010911
NCIt 47 C3329
UMLS 69 C0032000

Summaries for Pituitary Adenoma

MalaCards based summary : Pituitary Adenoma, also known as pituitary neoplasms, is related to pituitary adenoma, acth-secreting and neuritis. An important gene associated with Pituitary Adenoma is PRL (Prolactin), and among its related pathways/superpathways are Signaling by GPCR and IL-2 Pathway. The drugs Menthol and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 71 Pituitary adenomas are tumors that occur in the pituitary gland. Pituitary adenomas are generally... more...

Related Diseases for Pituitary Adenoma

Diseases related to Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 282)
id Related Disease Score Top Affiliating Genes
1 pituitary adenoma, acth-secreting 33.7 AIP GNAS IGF1 PRL SST
2 neuritis 29.9 SST SSTR2 SSTR5
3 pheochromocytoma 29.6 CRH MEN1 POMC SST
4 hypoglycemia 29.2 CRH DRD2 POMC
5 pituitary adenoma, growth hormone-secreting 12.4
6 familial isolated pituitary adenoma 12.4
7 pituitary adenoma, prolactin-secreting 12.3
8 pituitary adenoma, growth hormone-secreting 2 12.2
9 aip-related familial isolated pituitary adenomas 12.1
10 functioning pituitary adenoma 12.1
11 non-functioning pituitary adenoma 12.0
12 silent pituitary adenoma 12.0
13 functionless pituitary adenoma 11.8
14 null pituitary adenoma 11.8
15 chromophobe adenoma 11.4
16 acromegaly 11.3
17 cushing's syndrome 11.2
18 pituicytoma 11.2
19 chiasmal syndrome 11.2
20 adenoma 11.2
21 tsh producing pituitary tumor 11.0
22 somatomammotropinoma 11.0
23 acth-independent macronodular adrenal hyperplasia 10.9
24 hyperpituitarism 10.9
25 gastrointestinal defects and immunodeficiency syndrome 10.8
26 burning mouth syndrome type 3 10.3 POMC SST
27 atp7a-related copper transport disorders 10.3 AIP GNAS
28 renal hypoplasia, bilateral 10.3 POMC SST
29 spondyloepimetaphyseal dysplasia, isidor type 10.3 AIP MEN1
30 spondylometaphyseal dysplasia, czarny-ratajczak type 10.3 AIP MEN1
31 water-clear cell adenoma 10.3 POMC SST
32 grin2a-related speech disorders and epilepsy 10.3 GH1 GNAS PRL
33 vertebral artery occlusion 10.3 AIP POMC PRL
34 lung occult small cell carcinoma 10.3 DRD2 PRL SST
35 extragonadal nonseminomatous germ cell tumor 10.3 POMC PRL SST
36 vaginal adenoma 10.2 IGF1 POMC SST
37 shaver's disease 10.2 GH1 POU1F1
38 primary effusion lymphoma 10.2 GH1 GNAS IGF1
39 bone benign neoplasm 10.2 IGF1 POMC PRL
40 eccrine papillary adenocarcinoma 10.2 MEN1 POMC SST
41 plasmalogens synthesis deficiency isolated 10.2 GH1 POU1F1 PRL
42 pituitary apoplexy 10.2
43 thyroiditis 10.2
44 pituitary tumors 10.2
45 transmitted_by 10.2 DRD2 POMC PRL
46 ascariasis 10.2 SST SSTR2
47 african histoplasmosis 10.2 AIP POMC PRL SST
48 pemphigus vegetans 10.2 GH1 GHR SST
49 gershoni-baruch syndrome 10.2 PRL TRH
50 gangliocytoma 10.2

Graphical network of the top 20 diseases related to Pituitary Adenoma:



Diseases related to Pituitary Adenoma

Symptoms & Phenotypes for Pituitary Adenoma

MGI Mouse Phenotypes related to Pituitary Adenoma:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 SSTR5 TRH AIP CRH DRD2 GHR
2 growth/size/body region MP:0005378 10.33 AIP CRH DRD2 GHR GHRH GNAS
3 endocrine/exocrine gland MP:0005379 10.32 AIP CRH DRD2 GHR GHRH GNAS
4 cellular MP:0005384 10.19 AIP CRH DRD2 GHR GNAS IGF1
5 immune system MP:0005387 10.18 CRH DRD2 GHR GHRH GNAS IGF1
6 cardiovascular system MP:0005385 10.16 AIP DRD2 GHR GNAS IGF1 MEN1
7 adipose tissue MP:0005375 10.07 CRH DRD2 GHR GNAS IGF1 POMC
8 liver/biliary system MP:0005370 10.02 AIP CRH DRD2 GHR GHRH GNAS
9 integument MP:0010771 9.97 AIP CRH DRD2 GHR GNAS IGF1
10 nervous system MP:0003631 9.97 CRH DRD2 GHR GHRH GNAS IGF1
11 neoplasm MP:0002006 9.86 PRL AIP DRD2 GNAS IGF1 MEN1
12 reproductive system MP:0005389 9.61 TSHB DRD2 GHR GHRH IGF1 MEN1
13 skeleton MP:0005390 9.23 CRH DRD2 GHR GNAS IGF1 POU1F1

Drugs & Therapeutics for Pituitary Adenoma

Drugs for Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
3
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
4
Cabergoline Approved Phase 4,Phase 3,Phase 2,Early Phase 1 81409-90-7 54746
5
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
11
lanreotide Approved Phase 4,Phase 3 108736-35-2
12
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
13
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
14
Progesterone Approved, Vet_approved Phase 4,Phase 1,Phase 2 57-83-0 5994
15
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
16
Cefazolin Approved Phase 4 25953-19-9 656510 33255
17
Cefdinir Approved Phase 4 91832-40-5 6915944
18
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
19
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
20
Sulfamethoxazole Approved Phase 4 723-46-6 5329
21
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
22
Liraglutide Approved Phase 4 204656-20-2
23
Metformin Approved Phase 4 657-24-9 14219 4091
24
Zinc Approved Phase 4 7440-66-6 32051 23994
25
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
26
Methyltestosterone Approved Phase 4,Phase 3 58-18-4 6010
27
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
28
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
29
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
30
Ginseng Approved, Nutraceutical Phase 4 50647-08-0
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
32
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 54575, 6560146 143
33
Butyric Acid Experimental Phase 4 107-92-6 264
34 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1
35 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
36 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
37 Cortisol succinate Phase 4,Phase 3,Phase 2
38 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
39 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2
43 Hydrocortisone acetate Phase 4,Phase 3,Phase 2
44 Hydrocortisone-17-butyrate Phase 4
45 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
46 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
48 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
50 insulin Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 241)
id Name Status NCT ID Phase
1 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
3 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4
4 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4
5 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Completed NCT01861717 Phase 4
6 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4
7 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4
8 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4
9 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4
10 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4
11 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4
12 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4
13 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4
14 Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study Completed NCT02204826 Phase 4
15 A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency Completed NCT00455884 Phase 4
16 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4
17 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4
18 Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation Completed NCT00360074 Phase 4
19 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4
20 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4
21 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
22 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4
23 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4
24 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4
25 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4
26 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
27 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4
28 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4
29 Polycystic Ovary Syndrome (PCOS) and Sleep Apnea Terminated NCT00203996 Phase 4
30 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3
31 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3
32 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3
33 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3
34 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3
35 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3
36 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3
37 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3
38 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3
39 Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3
40 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
41 Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly Completed NCT00225979 Phase 3
42 Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women Completed NCT01653743 Phase 3
43 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3
44 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) Completed NCT00747617 Phase 3
45 Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients Completed NCT00128232 Phase 3
46 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3
47 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3
48 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3
49 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3
50 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3

Search NIH Clinical Center for Pituitary Adenoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: pituitary neoplasms

Genetic Tests for Pituitary Adenoma

Genetic tests related to Pituitary Adenoma:

id Genetic test Affiliating Genes
1 Pituitary Adenoma 29

Anatomical Context for Pituitary Adenoma

MalaCards organs/tissues related to Pituitary Adenoma:

39
Pituitary, Thyroid, Endothelial, Bone, Testes, Prostate, Brain

Publications for Pituitary Adenoma

Articles related to Pituitary Adenoma:

(show top 50) (show all 1583)
id Title Authors Year
1
Transdifferentiation of Neuroendocrine Cells: Gangliocytoma Associated With Two Pituitary Adenomas of Different Lineage in MEN1. ( 28079577 )
2017
2
Complex effects of apoplexy secondary to pituitary adenoma. ( 27802176 )
2017
3
Central hypogonadism due to a giant, "silent" FSH-secreting, atypical pituitary adenoma: effects of adenoma dissection and short-term Leydig cell stimulation by luteinizing hormone (LH) and human chorionic gonadotropin (hCG). ( 28067604 )
2017
4
Pituitary Adenoma and Hyperprolactinemia Accompanied by Idiopathic Granulomatous Mastitis. ( 28321344 )
2017
5
Mixed Gangliocytoma-Pituitary Adenoma: Insights on the Pathogenesis of a Rare Sellar Tumor. ( 28079576 )
2017
6
Pituitary adenoma with adipose tissue: A new metaplastic variant. ( 28070930 )
2017
7
An intrasellar pituitary adenoma-gangliocytoma presenting as acromegaly. ( 28469929 )
2017
8
A Case of Coincidental Intrasellar Chordoma and Pituitary Adenoma. ( 28516081 )
2017
9
Simultaneous Occurrence of a Pituitary Adenoma and a Foramen Magnum Meningioma: Case Report. ( 27989978 )
2017
10
Decreased TAp63 and I9Np63 mRNA Levels in Most Human Pituitary Adenomas Are Correlated with Notch3/Jagged1 Relative Expression. ( 28078618 )
2017
11
Does MMP-9 Gene Polymorphism Play a Role in Pituitary Adenoma Development? ( 28194042 )
2017
12
Relationship between RSUME and HIF-1I+/VEGF-A with invasion of pituitary adenoma. ( 27989771 )
2017
13
Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma. ( 27227698 )
2017
14
Increased I^a89catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach. ( 28260015 )
2017
15
Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report. ( 28061802 )
2017
16
The role of OsiriX based virtual endoscopy in planning endoscopic transsphenoidal surgery for pituitary adenoma. ( 27593805 )
2016
17
The role of FSCN1 in migration and invasion of pituitary adenomas. ( 26522130 )
2016
18
Lymphocytic hypophysitis in nonpregnant middle-aged females mimicking pituitary adenoma. ( 26732199 )
2016
19
Coexisting pituicytoma and pituitary adenoma; a second coincidence? ( 27189344 )
2016
20
Preoperative clonidine use in trans-sphenoidal pituitary adenoma surgeries - a randomized controlled trial. ( 27535352 )
2016
21
Ectopic Acromegaly Arising from a Pituitary Adenoma within the Bony Intersphenoid Septum of a Patient with Empty Sella Syndrome. ( 27468406 )
2016
22
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas. ( 27097804 )
2016
23
SNPs in the aryl hydrocarbon receptor-interacting protein gene associated with sporadic non-functioning pituitary adenoma. ( 26998050 )
2016
24
AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. ( 27080473 )
2016
25
Significance of TNF-I+ and IL-6 expression in invasive pituitary adenomas. ( 27050975 )
2016
26
Ectopic Suprasellar Thyrotropin-Secreting Pituitary Adenoma: Case Report and Literature Review. ( 27567574 )
2016
27
A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred. ( 27838609 )
2016
28
Predictive model for recovery of visual field after surgery of pituitary adenoma. ( 27476080 )
2016
29
Refractory pituitary adenoma: a novel classification for pituitary tumors. ( 27845901 )
2016
30
Polymorphisms in MEN1 and DRD2 genes are associated with the occurrence and characteristics of pituitary adenomas. ( 27185868 )
2016
31
Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma. ( 28005257 )
2016
32
Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. ( 26743473 )
2016
33
Coexisting pituicytoma and pituitary adenoma; a second coincidence?-reply. ( 27184480 )
2016
34
Coexistence of thyroid hormone resistance syndrome, pituitary adenoma and Graves' disease. ( 26786783 )
2016
35
Pituitary adenoma and non-acute headache: Is there an association, and does treatment help? ( 27132176 )
2016
36
Outcomes and Complications of Endoscopic Versus Microscopic Transsphenoidal Surgery in Pituitary Adenoma. ( 27213744 )
2016
37
Anterior and posterior suprasellar extensions of a symmetrical trilobed nonfunctional giant pituitary adenoma in the sagittal plane: a case report and review of literature. ( 27920872 )
2016
38
A patient with Cushing disease lateralizing a pituitary adenoma by inferior petrosal sinus sampling using desmopressin: a case report. ( 27104179 )
2016
39
Role of MMP-2 (-1306a88C/T) Polymorphism in Pituitary Adenoma. ( 27051552 )
2016
40
Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study. ( 27743172 )
2016
41
SU-G-TeP4-10: Do Small Errors Matter When Treating Pituitary Adenoma Patients Using Gamma Knife? ( 28047589 )
2016
42
Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma. ( 28012286 )
2016
43
Clinical Concerns about Recurrence of Non-Functioning Pituitary Adenoma. ( 27195254 )
2016
44
Preoperative Extrapontine Myelinolysis with Good Outcome in a Patient with Pituitary Adenoma. ( 26962424 )
2016
45
Growth hormone secreting pituitary adenoma with admixed gangliocytoma and ganglioglioma. ( 27068013 )
2016
46
Visual outcome after pituitary adenoma surgery. ( 27841195 )
2016
47
Time Course of Symptomatic Recovery after Endoscopic Transsphenoidal Surgery for Pituitary Adenoma Apoplexy in the Modern Era. ( 27663263 )
2016
48
Evaluation of Diffusivity in pituitary adenoma: 3D Turbo Field Echo with Diffusion-Sensitized Driven-Equilibrium Preparation. ( 27187598 )
2016
49
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells. ( 26522132 )
2016
50
Relationship of each anterior pituitary hormone deficiency to the size of non-functioning pituitary adenoma in the hospitalized patients. ( 27534814 )
2016

Variations for Pituitary Adenoma

Copy number variations for Pituitary Adenoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 55796 11 55700000 65900000 Copy number Pituitary adenoma
2 58390 11 67250504 67258578 Amplification AIP Pituitary adenoma
3 64485 12 12870301 12875305 Amplification CDKN1B Pituitary adenoma

Expression for Pituitary Adenoma

Search GEO for disease gene expression data for Pituitary Adenoma.

Pathways for Pituitary Adenoma

Pathways related to Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CRH DRD2 GHRH GNAS IGF1 MEN1
2
Show member pathways
13 GH1 GHR GNAS IGF1 PRKAR1A PRL
3
Show member pathways
12.71 CRH DRD2 GH1 GHR GHRH GNAS
4
Show member pathways
12.5 CRH GH1 GHRH GNAS POMC PRKAR1A
5
Show member pathways
12.08 DRD2 GNAS SSTR2 SSTR5
6
Show member pathways
11.97 GH1 IGF1 POMC TSHB
7 11.67 CRH GNAS POMC
8 11.6 POMC POU1F1 PRL
9 11.52 CRH GHRH GNAS POMC TSHB
10 11.48 GH1 GHR IGF1
11 11.39 CRH GNAS IGF1
12 11.24 GH1 GHRH GNAS IGF1 PRKAR1A
13
Show member pathways
11.11 GH1 GHR PRL
14 10.3 CRH POMC

GO Terms for Pituitary Adenoma

Cellular components related to Pituitary Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 CRH GH1 GHR GHRH IGF1 POMC
2 secretory granule GO:0030141 9.43 POMC PRL TRH
3 extracellular region GO:0005576 9.36 CRH GH1 GHR GHRH GNAS IGF1
4 endosome lumen GO:0031904 9.32 GH1 PRL
5 growth hormone receptor complex GO:0070195 8.96 GH1 GHR

Biological processes related to Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.91 CRH DRD2 GNAS PRL SST
2 negative regulation of cell proliferation GO:0008285 9.91 DRD2 MEN1 POU1F1 SST SSTR2 SSTR5
3 female pregnancy GO:0007565 9.8 CRH GNAS PRL
4 response to ethanol GO:0045471 9.8 CRH DRD2 PRL TRH
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.79 GH1 GHR IGF1
6 response to nutrient GO:0007584 9.79 PRL SST SSTR2
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 GH1 GHR IGF1
8 positive regulation of cAMP biosynthetic process GO:0030819 9.71 CRH GHRH GNAS
9 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.65 DRD2 GNAS
10 hormone-mediated signaling pathway GO:0009755 9.65 GHR TRH TSHB
11 synaptic transmission, dopaminergic GO:0001963 9.64 CRH DRD2
12 response to corticosterone GO:0051412 9.63 CRH TRH
13 insulin-like growth factor receptor signaling pathway GO:0048009 9.63 GHR IGF1
14 regulation of multicellular organism growth GO:0040014 9.63 GHR IGF1 PRL
15 cell-cell signaling GO:0007267 9.63 GHRH POMC SST SSTR2 TRH TSHB
16 parturition GO:0007567 9.61 CRH PRL
17 peristalsis GO:0030432 9.59 DRD2 SSTR2
18 positive regulation of growth hormone secretion GO:0060124 9.58 DRD2 GHRH
19 growth hormone receptor signaling pathway GO:0060396 9.58 GH1 GHR
20 positive regulation of JAK-STAT cascade GO:0046427 9.58 GH1 GHR PRL
21 somatostatin signaling pathway GO:0038170 9.56 SSTR2 SSTR5
22 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.54 GH1 GHR IGF1
23 hormone-mediated apoptotic signaling pathway GO:0008628 9.52 CRH SST
24 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.5 GH1 GHR PRL
25 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 GH1 GHRH IGF1
26 adenohypophysis development GO:0021984 9.13 DRD2 GHRH POU1F1
27 positive regulation of multicellular organism growth GO:0040018 9.02 DRD2 GH1 GHR GHRH POU1F1
28 signal transduction GO:0007165 10.2 AIP CRH DRD2 GNAS IGF1 POMC
29 G-protein coupled receptor signaling pathway GO:0007186 10.11 DRD2 GNAS SST SSTR2 SSTR5 TSHB
30 positive regulation of cell proliferation GO:0008284 10 CRH GHRH IGF1 POU1F1 PRL

Molecular functions related to Pituitary Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor receptor binding GO:0005159 9.32 GNAS IGF1
2 somatostatin receptor activity GO:0004994 9.26 SSTR2 SSTR5
3 hormone activity GO:0005179 9.23 CRH GH1 IGF1 POMC PRL SST
4 corticotropin-releasing hormone receptor 1 binding GO:0051430 9.16 CRH GNAS
5 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....